Working… Menu

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03439670
Recruitment Status : Active, not recruiting
First Posted : February 20, 2018
Last Update Posted : September 17, 2020
European Union
Cooperative International Neuromuscular Research Group
Newcastle University
University of Pittsburgh
Information provided by (Responsible Party):
ReveraGen BioPharma, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : February 24, 2021
Estimated Study Completion Date : August 1, 2021
Investigator's Brochure, Version 4, Vamorolone (17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione) 4% Oral Suspension, ReveraGen BioPharma, Inc., January 10, 2017.
FDA Draft Guidance for Industry: Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment. June 2015.